Cancer immunotherapy and a clinical trial dilemma
There is a numbers problem, and a biomarker one as well. Annually the worldwide cancer drug market is on the order of $110 Billion, and individual immuno-oncology drugs cost the US healthcare system on the order of $100K to $150K per year. With such large financial incentives, there are currently over 900 […]
